Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Reducing corticosteroid overuse in Spanish severe asthmatics: a pilot exploratory evaluation of the FOCUS program.

Created on 20 Nov 2026

Authors

José Luis Velasco Garrido, Sergio Campos Téllez, María Dolores Martínez Pitarch, Silvia Pascual Erquicia, Agustín Sojo González, Marta Robles Mañueco, Jose Luis Sanchez-Trincado Lopez

Published in

The Journal of asthma : official journal of the Association for the Care of Asthma. Pages 1-27. Nov 19, 2026. Epub Nov 19, 2026.

Abstract

The FOCUS program aimed to improve identification, referral, and management of patients with severe asthma and systemic corticosteroids (SCS) overuse (≥1 g/year), following the recommendations of the Spanish multidisciplinary consensus document on the use of SCS for severe asthma. This pilot exploratory investigation evaluated the implementation of the measures promoted by the program.
Aggregated data were collected through a questionnaire and interviews addressed to healthcare professionals (HCPs) experienced in managing severe asthma who participated in the FOCUS program.
Five pulmonologists completed the questionnaire; 80% visited >50 patients/month with asthma, of whom 60% presented severe asthma. HCPs indicated that 40% of these patients were poorly controlled, 48% required maintenance or cycles of SCS, and 21% received >1g/year of prednisone equivalent. Of those treated with biologics (47%), <30% required SCS.After FOCUS execution, all HCPs implemented protocols for management and referral to severe asthma units, an oral corticosteroids (OCS) calculator for annual OCS dose quantitation, and questionnaires for asthma control. These measures were evaluated as useful/very useful, improving patient management positively/very positively. Furthermore, 80% of HCPs reported that of patients already eligible for biologics, 26-50% initiated treatment with a biological agent; 60% of HCPs considered that 51-75% of patients with biologics reduced SCS overuse. Additionally, 80% of HCPs reported fewer exacerbations and emergency room visits and hospitalizations, and better asthma control.
In this pilot exploratory evaluation, participating HCPs perceived the FOCUS program as a potential benefit for patients with severe asthma, promoting reduction of SCS overuse and helping achieve better disease control.

PMID:
43056501
Bibliographic data and abstract were imported from PubMed on 20 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement